Two new patents for Implemed's technology:
This article was originally published in Clinica
Executive Summary
Implemed has received two additional US patents relating to its antimicrobial polymer technology. Used to develop anti-infective medical devices, the technology, known as Oligon, is based on a process called oligodynamic iontopheresis whereby silver ions are released to destroy microbes on the surface of a device. Implemed's first product using the technology, the Olimpicc peripherally inserted central venous catheter, is sold in Europe. The Watertown, Massachusetts-based company plans to develop partnerships and licensing opportunities to use its technology in a broader spectrum of medical devices.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.